Skip to content

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$158.92B-2.6%
Labcorp Holdings logo
Labcorp HoldingsLH
$28.24B+10.2%
Quest Diagnostics logo
Quest DiagnosticsDGX
$27.54B+9.5%
NeoGenomics logo
NeoGenomicsNEO
$883.35M-5.6%
Natera, Inc. logo
Natera, Inc.NTRA
$27.5B+49.9%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$7.64B-6.9%

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$552.11M-7.1%
P/S1.7×-0.3×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Calculated from Fulgent Genetics, Inc.’s reported figures.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s enterprise value?
Fulgent Genetics, Inc. (FLGT) reported enterprise value of $481.38M in Q1 2026.
How has Fulgent Genetics, Inc.'s enterprise value changed year-over-year?
Fulgent Genetics, Inc.'s enterprise value increased by 4.6% year-over-year, from $460.19M to $481.38M.
What is the long-term trend for Fulgent Genetics, Inc.'s enterprise value?
Over 5 years (2020 to 2025), Fulgent Genetics, Inc.'s enterprise value has grown at a -12.2% compound annual growth rate (CAGR), from $1.47B to $767.48M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.